PROVIDING EARLY ACCESS TO DRUGS IN DEVELOPMENT

 

ACCESS TO DRUGS IN DEVELOPMENT. REGISTER TO UNLOCK ALL INFORMATION.

PROVIDING EARLY ACCESS TO DRUGS IN DEVELOPMENT

myTomorrows provides physicians and patients that are excluded from clinical trials access to drugs in development. We focus on disease areas with unmet needs; oncology, neurology, psychiatry and rare diseases. myTomorrows identifies innovative drugs, informs physicians and patients and facilitates requests for access to these drugs in development.

REGISTER AT MYTOMORROWS

BUILDING A BRIDGE TO DRUG DEVELOPERS

genome

EXPANDED ACCESS PROGRAMS

Drug development takes about twelve years from discovery to marketing authorization. Drugs that show promising results during clinical development need to be tested in large patient populations before receiving marketing authorization. In many cases patients with high unmet medical needs that are excluded from clinical trials, can’t afford to wait the extra years it takes for a drug to receive such a marketing authorization.

Expanded Access Programs enable physicians and patients who have exhausted other medicinal treatment options to access development stage drugs or drugs that have marketing authorization elsewhere, but not yet in their home country.

LEARN MORE...

WHAT WE DO

Identify drug developments. Our physicians and bio-medical specialists identify the latest drug developments from across the globe.

Inform. Physicians and pharmacists can register online and request information about the drugs myTomorrows provides access to.

Facilitate requests. In most countries health authorities must grant permission for treatment with a non-registered drug. myTomorrows facilitates requests for permission for physicians and pharmacists.

WHO WE ARE

myTomorrows was founded by physicians and experts from the pharmaceutical industry who want to facilitate early access to the latest drug innovations for patients with high unmet needs, who are excluded from clinical trials. A newspaper article quote from an ALS patient needing access to not-yet-registered drugs was the inspiration for the company’s name: “I just want some more tomorrows”.

OUR MOTIVATION

Imagine. One of your relatives or friends is seriously ill and cannot be treated with available drugs. Some of the founders have been through this ordeal. Seriously ill patients are increasingly aware of the latest drug developments in their disease area. Sometimes patients can participate in clinical trials, but more often they cannot. For these patients and their physicians, myTomorrows is building a bridge to drug developers.

UNLOCK ALL INFORMATION

expanded access programs

BUILDING THE MOST COMPLETE EXPANDED ACCESS PROGRAM DATABASE IN THE WORLD

Search Made Easy

app-store-logo3

It is free…

IN THE PRESS